Vagus Nerve Stimulator Market By Product Type (Implantable Vagus Nerve Stimulator, Transcutaneous Vagus Nerve Stimulator (External)), By Application (Pain Management, epression & Anxiety, Epilepsy, Obesity, Others (Obstructive Sleep Apnea, Opioid Withdrawal)), By End-User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers) - Growth, Future Prospects, and Competitive Analysis, 2019 - 2027

The prevalence of neurological disorders has risen significantly on a global scale.

The global vagus nerve stimulator market is growing competently and is expected to grow at a CAGR of 7.4%. Globally, increasing open and minimally invasive neurological surgeries along with VNS therapies have significantly increased the revenue of vagus nerve stimulator devices. The increasing population globally, costs of medical expenditure for stroke and dementia, the burden of dyskinesia and neurological tremors, and new technology expansion will enhance the growth of the global vagus nerve stimulator market.

Market Synopsis

The implantable VNS segment is expected to register higher growth by the end of 2027.

In June 2017, the FDA approved LivaNova's vagus nerve stimulation therapy system for epilepsy in children as young as four years. Utilization of implantable VNS devices is associated with abnormal complexities such as dysrhythmia, paresthesia, cough, voice alteration, pain, and surgically related infections.

New and advanced vagus nerve stimulation devices (external) have been approved in Europe to treat depression, epilepsy, and pain. A similar, noninvasive device was recently approved by the FDA for the treatment of cluster headaches in the U.S. FDA approval of new products, higher efficacy of implantable devices, increasing applications for epilepsy, along with awareness, offer potential advantages as an elective treatment to high-cost surgical procedures.

The epilepsy segment is expected to register higher growth by the end of 2027.

The global market is witnessing a gradual shift towards modern VNS devices, and the demand for minimally invasive procedures has been rising over the past five years. Enhanced applications for partial epilepsy (aged 12 and older), generalized epilepsy, and Lennox-Gastaut syndrome (LGS) will drive the market's growth.

Developments in the field of VNS therapy, along with the usage and benefits of external device stimulation, will enhance the market growth. Vagus nerve stimulator devices can be utilized for normalizing other neurological conditions such as Crohn's disease, migraines, asthma, depression, and numerous cardiovascular diseases.

Increasing hospital admissions, rising medical expenditures, and the presence of top companies hold the U.S. in a dominant position.

In 2018, the U.S. generated maximum revenue in the vagus nerve stimulator market due to an increase in the prevalence of neurological disorders. The market in this region is driven by the significant prevalence of neurological disorders such as Parkinson's disease, Alzheimer's disease, depression, spinal cord injury, epilepsy, and traumatic brain injury in the U.S. market. Increasing procedures for intractable epilepsy and treatment-resistant depression, along with technological advancements in minimally invasive surgery, will drive market growth.

New technology expansion in the developing nations (mainly in the Asia Pacific region), a higher patient pool for brain-related disorders along with surgery, and enhanced applications for epileptic seizures, pain management, tinnitus, and depression and anxiety will drive the demand for implantable VNS devices in the near future.

Increased research and development with a strong product portfolio in the developed regions

Major players in the vagus nerve stimulator market are Medtronic Plc. and LivaNova Plc. BioControl Medical, EnteroMedics Inc., NERVANA LLC, ElectroCore LLC, Cerbomed GmbH, ReShape Lifesciences, Inc., Parasym Health, Innovative Health Solutions, Inc., Beijing PINS Medical Co., Ltd., Aleva Neurotherapeutics SA, and others Major implantable VNS device and external VNS device manufacturers are focused on producing top-quality products with enhanced biomaterials. Partnerships, product launches, and improved R&D will boost the development of vagus nerve stimulation in the near future.

Historical and Forecast Period

This study report represents an analysis of each segment from 2017 to 2027, considering 2018 to be the base year. The compound annual growth rate (CAGR) for each of the respective segments is estimated for the forecast period from 2019 to 2027.

Report Scope by Segments

Market Segmentation 

The current report also encompasses qualitative and qualitative market valuation factors such as key market drivers, market trends, restraints, and opportunities that give a better understanding of the overall vagus nerve stimulator market. Additionally, the global report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolios, and business strengths.

Key questions are answered in this report.

  • What are the current market trends and dynamics in the vagus nerve stimulator market, and what are the valuable opportunities for emerging players?
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which product type segment holds a larger market share and why?
  • Are low- and middle-income economies investing in the vagus nerve stimulator market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and the Middle East and Africa?

 Frequently Asked Question:

The market for Vagus Nerve Stimulator Market is expected to reach USD$ XX in 2027.

The Vagus Nerve Stimulatort Market is expected to see significant CAGR growth over the coming years, at 7.4%.

The report is forecasted from 2019 -2027.

The base year of this report is 2018.

EnteroMedics Inc., NERVANA LLC, ElectroCore LLC, Cerbomed GmbH, ReShape Lifesciences, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Aug 2019
Category:  Medical Devices
Report ID:   59840
Report Format:   PDF
Pages:   120
Rating:    4.4 (66)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support